Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 4Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Other solid neoplasm 1

Conditions

Breast Neoplasms 1774Neoplasms 1501Carcinoma, Non-Small-Cell Lung 1043Prostatic Neoplasms 957Colorectal Neoplasms 878Lung Neoplasms 800Pancreatic Neoplasms 572Carcinoma, Hepatocellular 542Leukemia, Myeloid, Acute 541Stomach Neoplasms 512Ovarian Neoplasms 507Neoplasm Metastasis 496Multiple Myeloma 495Recurrence 413Melanoma 386Squamous Cell Carcinoma of Head and Neck 370Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 355Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 305Endometrial Neoplasms 304Triple Negative Breast Neoplasms 299Glioblastoma 298Rectal Neoplasms 280Urinary Bladder Neoplasms 264Sarcoma 264Hematologic Neoplasms 264Colonic Neoplasms 254

Interventions

Paclitaxel 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Platinum-resistant Recurrent Ovarian Cancer × Clear all
NCT06434610 2026-05-05

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2 Recruiting
90 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

NCT06687070 2025-02-26

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Ascentage Pharma Group Inc.

Phase 1 Recruiting
50 enrolled
GynecologicOther solid neoplasm

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡